Narrator: This is Science Today. A new genomic test for prostate cancer has been evaluated by researchers at the University of California, San Francisco, and has been found to help predict whether men are more likely to have an aggressive form of the disease. Dr. Matt Cooperberg, who led the study, says the test can also help determine which men are suitable for active surveillance, which is a way to manage the disease without direct treatment.
Cooperberg: Most men with low risk disease actually don't need surgery or radiation therapy right off the bat. Most men with low-risk prostate cancer are actually best served with active surveillance.
Narrator: This means careful observation of the PSA levels, which doctors can monitor via blood tests every three to six months. And a biopsy is repeated every one to two years to make sure there is no sign of cancer progression.
Cooperberg: We need to do a better job targeting treatment to those patients who best need it. Men with low-risk disease frequently don't need any treatment and would do quite well with active surveillance.
Narrator: For Science Today, I'm Larissa Branin.